Design of 5' untranslated sequences in retroviral vectors developed for medical use.
about
The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cellsGene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzymeEfficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.The 17 nucleotides downstream from the env gene stop codon are important for murine leukemia virus packagingClonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells.Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in scid miceEfficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfectionGammaretroviral vectors: biology, technology and applicationAvoiding cytotoxicity of transposases by dose-controlled mRNA deliveryFetal liver-derived mesenchymal stem cell engraftment after allogeneic in utero transplantation into rabbitsHypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype.Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cellsSpontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneityStabilization of Transfected Cells Expressing Low-Incidence Blood Group Antigens: Novel Methods Facilitating Their Use as Reagent-Cells.Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.Phosphorylation of murine SAMHD1 regulates its antiretroviral activityAML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiencyCellular restriction of retrovirus particle-mediated mRNA transfer.Pbx1 is required for adult subventricular zone neurogenesis.Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells.Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner.Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packagingMus cervicolor murine leukemia virus isolate M813 belongs to a unique receptor interference group.Unmodified Cre recombinase crosses the membrane.In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity.Sodium-dependent myo-inositol transporter 1 is a cellular receptor for Mus cervicolor M813 murine leukemia virus.Limited complementarity between U1 snRNA and a retroviral 5' splice site permits its attenuation via RNA secondary structure.Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy.Differential control of Wnt target genes involves epigenetic mechanisms and selective promoter occupancy by T-cell factors.Lentiviral Vectors with Cellular Promoters Correct Anemia and Lethal Bone Marrow Failure in a Mouse Model for Diamond-Blackfan Anemia.Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
P2860
Q21090492-8F4DD944-ED8C-4B63-AC0A-DBDA848CBAB1Q33386724-0ACB2067-C313-427D-8D6C-0F4E49006E3CQ33496681-C9F90EB8-6646-4C41-BAA6-793C74E5CCD1Q33622730-A25A267E-91DC-408E-896E-7A611170B701Q33822282-DAC7C888-6DB1-4528-B987-B55638A60814Q33874608-DC18ED84-13A8-4D2F-B4BF-B8C834243381Q33908547-F1EE4297-33D9-487C-9006-2DB46B3E1992Q33922993-F4AE625B-2A1D-4532-AD0A-647D3E6C82E1Q33947981-1B1ABD98-3967-4215-BF6A-BDC460AE1594Q33952058-3E384776-9A26-4FDF-8897-6DB1D10E673EQ33968014-0C0296CC-B2DD-4C4C-B516-F1DB5EDCD758Q34204409-7FA8ECCF-7F8D-4D9D-A4AC-58FCDCD020A2Q34223822-429291A3-7EBB-4902-B5BA-A2313FF1032BQ35198350-615BDEFD-B6E4-4C54-8D8C-0DE9FF2934B6Q35673101-7E781B63-6B32-4EC5-9090-E7DD90867BF4Q35752656-951B3218-65A3-4D26-BA42-7CA6FC8E7B76Q35781480-B6040E0C-DAEE-48BD-872A-DD2288630563Q36044675-2710A4E6-EA97-4D1D-96D8-B795D82568C2Q36125276-A9165D5D-240C-410E-B039-BAC550DEC654Q36248825-2DCEBD41-05AE-4AAA-9648-BFA1A1CD65FAQ36370120-682E16CA-A1CC-4A23-985E-C1129458F091Q36371457-3F37D4A2-4040-4C82-A9C6-9F486F5999E3Q36484018-4A289F19-375C-4EC6-802F-1977B1E7EEA4Q37120436-4E052D4B-7867-42D3-ABCE-21A0C49333B9Q37201960-2E602980-16B4-4C93-A611-52A0EEFCE8FEQ38316167-30139D5F-F71D-4FE2-A91B-25854AAB58B1Q39590160-437FA93A-4BE1-4D76-BBEC-949A4C991DC0Q39602612-D5089B06-E580-4D0A-AB7F-FFF087B4D8ECQ39616039-0AE8230B-1385-4801-94AC-5B63F3E6BFBEQ39681695-C5EFD03B-7E6A-48F5-A050-F7AEF33DE5A4Q39748917-B6B5124C-F933-4B0E-8256-C5A749046DBCQ39783741-225B88EB-0140-4177-9AE4-B7694C122F1AQ40035980-48DF2DA2-2E82-4752-8290-7412A3F1B84DQ40070408-A738DF43-82C5-473A-9DC1-BD3CB02A6155Q40231073-E4FFA080-DC5E-4604-B607-254A684435B6Q40604434-A9865057-4A7B-4AEC-9CA3-D69DD9A1351DQ43964931-C8E046DA-653F-4465-A0B6-E4F2E02A01A1
P2860
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@en
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@nl
type
label
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@en
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@nl
prefLabel
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@en
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@nl
P2093
P2860
P1433
P1476
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
@en
P2093
P2860
P304
P407
P577
1999-05-01T00:00:00Z